anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Fluoxetine Hydrochloride
Trial phase: Phase 1
SMILES: CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1.Cl
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: Participants, in Cohort 5, who received two 20-mg LY110140 (fluoxetine hydrochloride) capsules, orally administered once daily for 28 days, during the MD period. On Days 1 and 28 participants were required to fast at least 8 hours prior to dosing and 4 hours postdose.
Eligibility criteria:
Inclusion Criteria:

Overtly healthy Japanese males (as determined by medical history and physical examination) who agree to use a reliable method of birth control during the study and for 3 months following the last dose of the investigational product.
Have a body mass index (BMI) of 18.5 to 29.9 kilograms per square meter (kg/m^2), inclusive, at the time of screening.
Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the study site.

Exclusion Criteria:

Poor metabolizers of isoenzyme cytochrome P450 2D6 (CYP2D6) (assessed at screening).
Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participating in the study such as, a Bazett's corrected QT (QTcB) interval >450 milliseconds (msec).
Have any lifetime history of a suicide attempt, or have suicidal ideation or, any suicidal behavior within the last month, or who are at significant risk to commit suicide, as judged by the investigator using the Columbia Suicide Severity Rating Scale (C-SSRS).
Are unsuitable (in the opinion of the investigator or sponsor) for inclusion in the study.
Intervention: Epinastine Hydrochloride
Trial phase: Phase 4
SMILES: Cl.NC1=NCC2c3ccccc3Cc3ccccc3N12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis

ELESTAT® (epinastine HCl ophthalmic solution) 0.05%: 1 drop on single occasion after exposure to grass pollen
Eligibility criteria:
Inclusion Criteria:

history of seasonal allergic conjunctivitis or seasonal allergic rhinoconjunctivitis (seasonal hay fever) that is not currently active.

Exclusion Criteria:

eye surgery in the last 3 months
active eye condition
adverse reaction to ocular drugs or dyes
history of anaphylaxis (severe systemic allergic reaction)
use any ocular medication or systemic medications (antihistamines, mast cell stabilisers, non-steroidal anti-inflammatory drugs or steroids) at least 14 days prior to the start and for the duration of the study
Intervention: Gefapixant
Trial phase: Phase 2
ATC code: G01AE10 | R05DB29
SMILES: COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 54
Group description: Female participants receive gefapixant, a total dose titrated from 50 mg to highest tolerated dose (maximum of 300 mg) twice daily (BID), orally over a period of 6 days with food depending on safety and tolerability, and then maintain that dose for the course of a 4-week treatment period. Participants were allowed to decrease the dose if tolerability issues occurred.
Eligibility criteria:
Inclusion Criteria:

Women
Women of child bearing potential must not be pregnant during the study and must use two forms of birth control
Clinical evidence of Interstitial Cystitis /Bladder Pain Syndrome (IC/BPS)
Have provided written informed consent

Exclusion Criteria:

History of diseases that can be confused for IC/BPS
Unable to void spontaneously
Immunosuppressant, intravesicular, nerve stimulator or opioid treatment for certain periods prior to start of the study
Changes to doses of Elmiron®, antidepressant, alpha-adrenergic antagonist, H1 antagonist, or anti-muscarinic treatment within a certain period prior to the start of the study
Intervention: Basaglar
Trial phase: Phase 3
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NCC(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: The trial included a screening period of approximately one week, a run-in period of 4 weeks followed by 2 treatment periods of 6 weeks each in a cross-over design, and a follow-up visit no less than 7 days after the last treatment visit. Total trial duration for the individual subject was 18 weeks.

Treatment period A: Subjects from run-in period were randomised to IGlar OD (100 U/mL, 3 mL SoloStar® prefilled pen s.c., morning dose) in combination with mealtime IAsp (100 U/mL, prefilled pen s.c.) for 6 weeks.

Treatment period B: Subjects (from treatment period A) were crossed over to IDeg OD (100 U/mL, prefilled pen s.c., morning dose) for 6 weeks in combination with mealtime IAsp (100 U/mL, prefilled pen s.c.) for 6 weeks.
Eligibility criteria:
Inclusion Criteria:

Type 1 diabetes
HbA1c (glycosylated haemoglobin) below or equal to 8.5%
Current treatment with IGlar (insulin glargine) in a basal-bolus regimen with a total daily dose below 120 U
BMI (body mass index) below 35 kg/m^2

Exclusion Criteria:

Use within the last 3 months prior to visit 1 (screening) of any antidiabetic glucose lowering drug other than insulin/insulin analogues
Subjects with regular use of acetaminophen who are not willing to use another analgetic during CGM (Continuous Glucose Monitoring) periods
Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronary arterial bypass graft or angioplasty within 24 weeks prior to visit 1
Recurrent severe hypoglycemia (more than one severe hypoglycemic event during the last 12 months) or hypoglycemia unawareness or hospitalization for diabetic ketoacidosis during the previous 6 months
Intervention: Aliskiren
Trial phase: Phase 4
ATC code: C09DX02 | C09XA02 | C09XA52 | C09XA53 | C09XA54
SMILES: COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 295
Group description: Aliskiren 300 mg once daily, taken 30 minutes after start of light breakfast
Eligibility criteria:
Inclusion Criteria:

Patients with essential hypertension, untreated or currently taking antihypertensive therapy (monotherapy or combination therapy).
Patients with an office BP ≥ 140/90 mmHg and < 180/110mmHg at the randomization visit and the preceding visit
Patients must have an absolute difference of ≤ 10 mmHg in both their msSBP and their msDBP between the randomization visit and the preceding visit

Exclusion Criteria:

Malignant hypertension or severe hypertension (grade 3 of WHO classification; msSBP ≥180 mmHg or msDBP ≥110 mmHg)
History or evidence of a secondary form of hypertension, such as renal parenchymal hypertension, renovascular hypertension, coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, drug-induced hypertension, unilateral or bilateral renal artery stenosis, pheochromocytoma, polycystic kidney disease (PKD).
Type 1 or Type 2 diabetes mellitus with a fasting glycosylated hemoglobin (HbA1c) > 8%
Evidence of renal impairment as determined by one of the following: serum creatinine >1.5 x ULN or eGFR < 30 ml/min/1.73m2 at Visit 1, a history of dialysis, or a history of nephrotic syndrome

Other protocol-defined inclusion/exclusion criteria may apply.

-
Intervention: Aliskiren
Trial phase: Phase 4
ATC code: C09DX02 | C09XA02 | C09XA52 | C09XA53 | C09XA54
SMILES: COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 294
Group description: Aliskiren 300 mg once daily taken after after an overnight fast
Eligibility criteria:
Inclusion Criteria:

Patients with essential hypertension, untreated or currently taking antihypertensive therapy (monotherapy or combination therapy).
Patients with an office BP ≥ 140/90 mmHg and < 180/110mmHg at the randomization visit and the preceding visit
Patients must have an absolute difference of ≤ 10 mmHg in both their msSBP and their msDBP between the randomization visit and the preceding visit

Exclusion Criteria:

Malignant hypertension or severe hypertension (grade 3 of WHO classification; msSBP ≥180 mmHg or msDBP ≥110 mmHg)
History or evidence of a secondary form of hypertension, such as renal parenchymal hypertension, renovascular hypertension, coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, drug-induced hypertension, unilateral or bilateral renal artery stenosis, pheochromocytoma, polycystic kidney disease (PKD).
Type 1 or Type 2 diabetes mellitus with a fasting glycosylated hemoglobin (HbA1c) > 8%
Evidence of renal impairment as determined by one of the following: serum creatinine >1.5 x ULN or eGFR < 30 ml/min/1.73m2 at Visit 1, a history of dialysis, or a history of nephrotic syndrome

Other protocol-defined inclusion/exclusion criteria may apply.

-
Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Patients in this group receive Ozurdex at initial visit and at month 4

dexamethasone intravitreal implant: Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
Eligibility criteria:
Inclusion Criteria:

Presence of NPDR or PDR as confirmed by fluorescein angiography
Prior treatment with >= 2 intravitreal anti-VEGF injections but no treatment in last 4 weeks
< 0.1 LogOCT decrease in macular edema on high resolution OCT between initial visit and following treatment with >= 2 intravitreal anti-VEGF injections
Age 18 years or older
ETDRS Visual acuity between 3 and 78 letters (approximate Snellen equivalent of 20/25 to 20/800)
Ability to provide written informed consent
Capable of complying with study protocol.

Exclusion Criteria:

Intraocular injection of steroid medication within prior 3 months
Evidence of significant geographic atrophy on fluorescein angiography in the opinion of the treating physician
Concurrent ocular disease (wet AMD, significant ERM, etc) that would limit visual acuity in the opinion of the treating physician
Prior vitrectomy surgery
Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to day 1.
Known history of IOP elevation in response to steroid treatment in either eye that resulted in any of the following: a) = 10 mm Hg increase in IOP in response to steroid injection, or b) IOP = 25 mm Hg and required 2 or more anti-glaucoma medications to keep IOP below 21 mm Hg.
Patients who are pregnant.
Unwilling or unable to follow or comply with all study related procedures
Intervention: Roflumilast
Trial phase: Not Applicable
ATC code: R03DX07
SMILES: O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: roflumilast: The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
Eligibility criteria:
Inclusion Criteria:

Male and female subjects, > 40 years of age

Clinical diagnosis of moderate to severe COPD as defined by the GOLD criteria:

Post-bronchodilator FEV1/FVC < 70% Post-bronchodilator FEV1 < 70% predicted

Cigarette consumption of 10 pack-years or more. Patients may be active smokers.
The presence of chronic cough and sputum production
Willingness to make return visits and telephone availability for the study duration

Exclusion Criteria:

A diagnosis of asthma as established by the study investigator on the basis of the recent American Thoracic Society/European Respiratory Society guidelines
Clinically significant bronchiectasis
Oxygen use >12 hours/day
Known sensitivity to roflumilast
Use of other methylxanthines within 1 month (theophylline)
Changes to current maintenance COPD therapy within one month
Pregnancy
An acute illness requiring antibiotics and/or corticosteroids within the month prior to enrolment.

Immunosuppression

HIV
Solid organ transplant
Active malignancy
Systemic corticosteroid use ≥ prednisone 20mg / day
Other immunosuppressants
Terminal illness defined as anticipated survival <12 months

Severe comorbidities including uncontrolled angina, congestive heart failure, end-stage renal disease, liver failure, or other conditions that would preclude the patient from safely completing the required tests or the study.

-
Intervention: Gabapentin
Trial phase: Phase 4
ATC code: N02BF01 | N03AX12
SMILES: NCC1(CC(=O)O)CCCCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: 300mg qid x 3 days, 300mg tid x 1 day, 300mg bid x 1 day, 300mg hs x 1 day then d/c
Eligibility criteria:
Inclusion Criteria:

Alcohol dependent at risk for withdrawal symptoms

Exclusion Criteria:

Benzodiazepine dependent
Intervention: Lovenox
Trial phase: Phase 3
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: enoxaparin 0.4 ml subcutaneous per day

Enoxaparin: enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
Eligibility criteria:
Inclusion Criteria:

Intracranial spontaneous hemorrhage on brain CT scan
Intracranial hemorrhage during treatment with oral anticoagulants
Bedridden patients (item 6 of NIHSS: motor leg points 3 or 4 or severe ataxia for cerebellar hemorrhage).

Exclusion Criteria:

cerebral hemorrhage due to intracranial vascular malformation
rebleeding on CT scan after 72 hours from stroke (before randomization)
Intervention: Testosterone
Trial phase: Phase 3
ATC code: G03BA03 | G03EA02
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: Patients receive testosterone (0.264mL) topical application daily for six months.
Eligibility criteria:
Inclusion Criteria:

Age ≥ 18 years
Receiving anastrozole (1mg) or letrozole (2.5 mg) orally once a day, for ≥ 21 days prior to registration and plan to continue it throughout the duration of study
Body Mass Index (BMI) between 18 and 35 kg/m^2
Women who have undergone a total mastectomy or breast conserving surgery for primary breast cancer +/-chemo, +/-radiotherapy.
Must have BOTH ER and PR receptor-positive tumors and BOTH must be ≥26% positive. Alternatively, if ER and PR are determined by Allred score, the score needs to be 5 or higher
Women who are postmenopausal by surgery, radiotherapy or presence of natural amenorrhea ≥ 12 months
≥ 5/10 arthralgia (in hands, wrist, knees, or hips) while being treated with anastrozole or letrozole which is felt by the patient to be caused by their aromatase inhibitor as defined in the protocol. Note: Patients may, or may not, be taking non-opioid analgesics
Ability to complete questionnaire(s) by themselves or with assistance
ECOG Performance Status (PS) 0, 1 or 2
Willing to provide informed written consent
Willing to return to an Alliance enrolling institution for follow-up
Willing to provide blood samples for correlative research purposes

Laboratory values prior to registration as defined in the protocol:

Creatinine ≤1.5 x ULN
Hemoglobin > 11 g/dL
WBC > 3.0
Platelet Count > 100,000
SGOT (AST) ≤ 1.5 x ULN

Exclusion Criteria:

Presence of residual or recurrent cancer (locally or metastatic)
Diabetes mellitus or glucose intolerance, defined as a fasting glucose >125 mg/dL
History of coronary artery disease (angina or myocardial infarction)
Patients on hormone replacement therapy (HRT) ≤ 4 weeks prior to registration. This includes the use of vaginal estrogen therapy.
Known hypersensitivity to any component of testosterone.
Prolonged systemic corticosteroid treatment, except for topical applications (e.g. for rash), inhaled sprays (e.g. for obstructive airway diseases), eye drops or local insertion (e.g. intra-articular). Note: Short duration (< 2 weeks) of systemic corticosteroids is allowed (e.g. for chronic obstructive pulmonary disease) but not within 30 days prior to registration.
Receiving any other investigational agent
History of a deep venous thrombosis or a thromboembolism
Concurrent use of the aromatase inhibitor exemestane, as it is structurally similar to an androgen
Concurrent radiation therapy or chemotherapy
Current or planned use of cyclosporine, anticoagulants, oxphenbutazone, insulin, oral or injectable vitamin D doses over 4,000IU/day, or tamoxifen
Intervention: Moxifloxacin Hydrochloride
Trial phase: Phase 3
SMILES: COc1c(N2CC3CCCNC3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 489
Group description: 1 drop instilled TID in each eye for 7 days with a TOC at Day 9
Eligibility criteria:
Inclusion Criteria:

Chinese.
Diagnosis of bacterial conjunctivitis based on clinical observation.
Understand and sign the approved informed consent. Legally authorized representative can provide informed consent for patients less than 18 years old and/or incapable of understanding the informed consent.
Willing to complete all required study procedures and visits.
Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

Women who are pregnant, lactating, or planning a pregnancy.
Only 1 sighted eye or vision not correctable to 0.6 logMAR or better in either eye.
Planned contact lens wear during the course of the study.
Signs and symptoms of bacterial conjunctivitis for longer than 4 days prior to Screening (Day 1).
Suspected fungal, viral, or Acanthamoeba infection.
Any systemic or ocular disease or disorder, complicating factor or structural abnormality that would negatively affect the conduct or outcome of the study.
History of recent surgery.
Presence of concomitant systemic viral infection.
Other protocol-defined exclusion criteria may apply.
Intervention: SODIUM BICARBONATE
Trial phase: Not Applicable
ATC code: B05CB04 | B05XA02
SMILES: O=C([O-])O.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 74
Group description: Sodium bicarbonate: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
Eligibility criteria:
Inclusion Criteria:

Veteran
Age older than 18 years
Diabetes mellitus
Serum bicarbonate 22 - 28 mmol/L on the most recent measurement within the past six months
Stage 2, 3, or 4 CKD (defined as estimated glomerular filtration rate (eGFR) 15 - 89 ml/min/1.73m2 using the CKD-Epidemiology equation)
Urinary albumin:creatinine ratio > 30 mg/gm on the most recent sample within the past 12 months.

Exclusion Criteria:

Lean body weight > 100 kg
Use of oral medications typically prescribed to raise low serum bicarbonate levels (i.e. sodium bicarbonate, sodium citrate, potassium citrate).
Serum potassium < 3.5 meq/L at enrollment visit
Use of 5 or more antihypertensive agents, regardless of the indications of each agent
Systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg at the enrollment or baseline visit
Diagnosis of congestive heart failure with current, active Class III or IV New York Heart Association symptoms.
Significant fluid overload such that it is unsafe in the opinion of the PI for the patient to participate in the trial
chronic gastrointestinal disorder or any other factors judged to be likely to limit adherence to interventions (i.e. alcoholism, a history of missing clinic visits)
Chronic immunosuppressive therapy for transplanted organs or other indications

Individuals who are currently a member of a vulnerable population (I.e. incarcerated, pregnant).

11.Currently participating in another interventional research study
Intervention: ICATIBANT
Trial phase: Phase 4
ATC code: B06AC02
SMILES: NC(N)=NCCCC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)N1CC(O)CC1C(=O)NCC(=O)NC(Cc1cccs1)C(=O)NC(CO)C(=O)N1Cc2ccccc2CC1C(=O)N1C(C(=O)NC(CCCN=C(N)N)C(=O)O)CC2CCCCC21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: 30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization

icatibant: Subcutaneous at time 0 and 6 hours
Eligibility criteria:
Inclusion Criteria:

The subject has ongoing angioedema while taking an ACE inhibitor.
The subject is between 18 and 80 years of age.

Exclusion Criteria:

The subject has had angioedema while not taking an ACE inhibitor.
The subject's angioedema only involves the bowel.
The subject is known to be pregnant or has a positive urine pregnancy test.
The subject has started on an oral contraceptive within the last 6 months.
Intervention: Fluciclovine (18F)
Trial phase: Not Applicable
ATC code: V09IX12
SMILES: N[C@]1(C(=O)O)C[C@@H]([18F])C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: FACBC: Drug is give intravenously over 2 minutes at time of scan
Eligibility criteria:
Inclusion Criteria:

Patients must be 18 years of age or older.
Patients will have biochemical and/or clinical evidence of primary hyperparathyroidism and be a surgical candidate for definitive parathyroid surgery .
Ability to lie still for PET scanning
Patients must be able to provide written informed consent

Exclusion Criteria:

Age less than 18.
Inability to lie still for PET scanning.
Cannot provide written informed consent.
History of secondary hyperparathyroidism.
Positive serum or urine pregnancy test within 24 hours of imaging